ASN General Discussion, page-19565

First 19565 Last

Share
Profile

Follow
jnene

3,996 Posts.

876

10/05/24

21:57

Post #: 73772224
Share

Originally posted by bgr980: ↑

I agree TT that the market doesn't understand it.... yet.

Interested to see what happens to the share price when the penny drops that ASN:

- Is on its way to production
- Offtakers are signing up due to IRA benefit
- Offtakers are signing up due to being an environmentally friendly operation
- Offtakers have close proximity to their lithium source
- More customers to join the ranks of LG Energy
- Range of other minerals on offer in stage 2
- Uranium project on Brownfields site, close proximity to operating mill in favourable domestic conditions due to Russia ban.
- Utah Brine Bill implementation
- Two projects in Paradox and Green River
- Funding within the next 6-10 months (or sooner), potentially government.
- Offtaker investment / contribution to CAPEX
- Approx $161 mil market cap

Noticed that VUL has started to turn from the lows in Feb, same time as ASN. Would be great to have a rotation of capital into the sector to compliment the run of news in front of us.

Just some thoughts, not advice. Getting excited as I feel like the home stretch to further derisking is getting closer and closer.

Cheers

Expand

brilliant summary BG !!

Originally posted by bgr980: ↑

I agree TT that the market doesn't understand it.... yet.

Interested to see what happens to the share price when the penny drops that ASN:

- Is on its way to production
- Offtakers are signing up due to IRA benefit
- Offtakers are signing up due to being an environmentally friendly operation
- Offtakers have close proximity to their lithium source
- More customers to join the ranks of LG Energy
- Range of other minerals on offer in stage 2
- Uranium project on Brownfields site, close proximity to operating mill in favourable domestic conditions due to Russia ban.
- Utah Brine Bill implementation
- Two projects in Paradox and Green River
- Funding within the next 6-10 months (or sooner), potentially government.
- Offtaker investment / contribution to CAPEX
- Approx $161 mil market cap

Noticed that VUL has started to turn from the lows in Feb, same time as ASN. Would be great to have a rotation of capital into the sector to compliment the run of news in front of us.

Just some thoughts, not advice. Getting excited as I feel like the home stretch to further derisking is getting closer and closer.

Cheers

Expand

ASN Price at posting: 13.3¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 2,159 more messages in this thread...

First 19565 Last

Add ASN (ASX) to my watchlist

(20min delay)
Last 7.7¢		Change 0.003(4.05%)		Mkt cap ! $102.9M

Open	High	Low	Value	Volume
7.5¢	7.7¢	7.5¢	$162.5K	2.151M

Buyers (Bids)

No.	Vol.	Price($)
3	64533	7.6¢

Sellers (Offers)

Price($)	Vol.	No.
7.7¢	227952	2

View Market Depth

No.	Vol.	Price($)
3	64533	0.076
3	300680	0.075
11	786453	0.074
8	650423	0.073
10	761506	0.072

Price($)	Vol.	No.
0.077	227952	2
0.079	583307	5
0.080	1193808	4
0.081	1226780	5
0.082	300000	1

Last trade - 16.10pm 07/10/2024 (20 minute delay)

ASN (ASX) Chart

ASN General Discussion, page-19565

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

ASN General Discussion, page-19565

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News